ETF Holdings Breakdown of URGN

URGN institutional holdings

The following institutional investment holdings of URGN have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	30,790	USD 727,568	23.63
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	30,790	USD 727,568 2.1%	23.63
Total =		61,580	USD 1,455,136

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with URGN

Urogen Pharma (NASDAQ:URGN) Trading Down 8% After Insider Selling

Urogen Pharma (NASDAQ:URGN – Get Free Report) traded down 8% on Wednesday following insider selling activity. The stock traded as low as $19.25 and last traded at $19.04. 265,793 shares were traded during mid-day trading, a decline of 83% from the average session volume of 1,523,562 shares. The stock had previously closed at $20.69. Specifically, […] - 2025-09-12 02:22:45

Urogen Pharma (NASDAQ:URGN) Receives $32.00 Consensus PT from Analysts

Urogen Pharma (NASDAQ:URGN – Get Free Report) has earned a consensus rating of “Buy” from the nine brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The […] - 2025-09-10 02:33:00

XTX Topco Ltd Raises Position in Urogen Pharma (NASDAQ:URGN)

XTX Topco Ltd grew its holdings in shares of Urogen Pharma (NASDAQ:URGN – Free Report) by 39.3% in the 1st quarter, HoldingsChannel.com reports. The firm owned 25,967 shares of the company’s stock after purchasing an additional 7,326 shares during the quarter. XTX Topco Ltd’s holdings in Urogen Pharma were worth $287,000 as of its most […] - 2025-08-11 05:44:58

Urogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% After Earnings Miss

Urogen Pharma (NASDAQ:URGN – Get Free Report)’s stock price dropped 14.4% during trading on Thursday following a dissappointing earnings announcement. The stock traded as low as $18.59 and last traded at $17.12. Approximately 366,073 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 1,583,408 shares. The stock had […] - 2025-08-08 04:46:54

Urogen Pharma (NASDAQ:URGN) Earns Buy Rating from D. Boral Capital

Urogen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $25.00 target price on the stock. D. Boral Capital’s price target points to a potential upside of 24.94% from the stock’s previous close. […] - 2025-08-07 03:14:58

Urogen Pharma (NASDAQ:URGN) Receives $32.86 Consensus PT from Analysts

Urogen Pharma (NASDAQ:URGN – Get Free Report) has been given an average rating of “Buy” by the eight research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-07-22 02:25:21

UroGen Pharma Announces Data Of Phase 2b Of Bladder Cancer Study

(RTTNews) - UroGen Pharma Ltd. (URGN), Monday announced results of a five-year long-term extension study of the Phase 2b OPTIMA II trial, evaluating ZUSDURI for intravesical solution in patients with low-grade intermediate-risk non-muscle invasive bladder cancer. - 2025-07-21 10:42:58

Alps Advisors Inc. Reduces Holdings in Urogen Pharma (NASDAQ:URGN)

Alps Advisors Inc. reduced its stake in shares of Urogen Pharma (NASDAQ:URGN – Free Report) by 4.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,762 shares of the company’s stock after selling 1,359 shares during the period. Alps Advisors Inc. owned […] - 2025-07-16 05:23:13

Brokerages Set Urogen Pharma (NASDAQ:URGN) PT at $32.86

Urogen Pharma (NASDAQ:URGN – Get Free Report) has earned a consensus recommendation of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The […] - 2025-06-27 02:37:05

Urogen Pharma (NASDAQ:URGN) Short Interest Down 29.9% in May

Urogen Pharma (NASDAQ:URGN – Get Free Report) was the recipient of a large drop in short interest in the month of May. As of May 31st, there was short interest totalling 3,920,000 shares, a drop of 29.9% from the May 15th total of 5,590,000 shares. Based on an average daily volume of 1,670,000 shares, the […] - 2025-06-19 02:54:55

Urogen Pharma (NASDAQ:URGN) Sees Strong Trading Volume After Analyst Upgrade

Shares of Urogen Pharma (NASDAQ:URGN – Get Free Report) saw unusually-high trading volume on Monday after HC Wainwright upgraded the stock from a neutral rating to a buy rating. HC Wainwright now has a $50.00 price target on the stock. Approximately 2,166,518 shares were traded during trading, an increase of 119% from the previous session’s […] - 2025-06-18 02:10:51

UroGen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, Scotiabank Analyst Says

UroGen Pharma (NASDAQ:URGN – Free Report) had its price target hoisted by Scotiabank from $23.00 to $47.00 in a research note issued to investors on Friday morning,Benzinga reports. Scotiabank currently has a sector outperform rating on the stock. Several other equities analysts have also issued reports on the company. D. Boral Capital reiterated a “buy” […] - 2025-06-16 02:30:47

UroGen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, Guggenheim Analyst Says

UroGen Pharma (NASDAQ:URGN – Free Report) had its price target upped by Guggenheim from $15.00 to $30.00 in a research note published on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other equities research analysts have also recently commented on URGN. LADENBURG THALM/SH SH initiated coverage on UroGen Pharma […] - 2025-06-16 02:30:47

Two Sigma Investments LP Sells 30,139 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Two Sigma Investments LP trimmed its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 34.6% in the 4th quarter, Holdings Channel reports. The firm owned 56,895 shares of the company’s stock after selling 30,139 shares during the quarter. Two Sigma Investments LP’s holdings in UroGen Pharma were worth $606,000 at the […] - 2025-06-09 04:56:44

UroGen Pharma (NASDAQ:URGN) Given New $10.00 Price Target at Oppenheimer

UroGen Pharma (NASDAQ:URGN – Get Free Report) had its price objective cut by Oppenheimer from $36.00 to $10.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s price objective would suggest a potential upside of 103.25% from the company’s previous close. A number of other […] - 2025-06-05 02:16:56

Ameriprise Financial Inc. Has $523,000 Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

Ameriprise Financial Inc. lifted its holdings in UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 9.3% during the 4th quarter, HoldingsChannel reports. The fund owned 49,153 shares of the company’s stock after acquiring an additional 4,188 shares during the quarter. Ameriprise Financial Inc.’s holdings in UroGen Pharma were worth $523,000 as of its most recent […] - 2025-06-04 05:48:46

UroGen Pharma Ltd. (NASDAQ:URGN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy […] - 2025-05-30 02:10:58

UroGen Pharma Ltd. (NASDAQ:URGN) Shares Sold by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. cut its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 14.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 24,481 shares of the company’s stock after selling 4,131 shares during the period. Balyasny […] - 2025-05-18 05:45:17

UroGen Pharma (NASDAQ:URGN) Earns Buy Rating from HC Wainwright

UroGen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $55.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 457.24% from the company’s previous close. URGN has been […] - 2025-05-15 02:48:49

UroGen Pharma (NASDAQ:URGN) Shares Gap Down on Disappointing Earnings

UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) shares gapped down before the market opened on Monday following a weaker than expected earnings announcement. The stock had previously closed at $10.38, but opened at $9.90. UroGen Pharma shares last traded at $11.19, with a volume of 402,553 shares trading hands. The company reported ($0.92) earnings […] - 2025-05-14 02:22:54

MetLife Investment Management LLC Buys 2,727 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

MetLife Investment Management LLC increased its stake in UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 13.6% during the fourth quarter, HoldingsChannel reports. The firm owned 22,766 shares of the company’s stock after acquiring an additional 2,727 shares during the period. MetLife Investment Management LLC’s holdings in UroGen Pharma were worth $242,000 as of its […] - 2025-05-08 05:02:47

UroGen Pharma Ltd. (NASDAQ:URGN) Receives $32.86 Average PT from Analysts

Shares of UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) have received an average rating of “Buy” from the eight brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. […] - 2025-05-08 02:52:55

Alliancebernstein L.P. Acquires 175,859 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Alliancebernstein L.P. grew its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 751.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 199,259 shares of the company’s stock after acquiring an additional 175,859 shares during the quarter. Alliancebernstein L.P.’s holdings in UroGen Pharma were worth $2,122,000 at the end […] - 2025-04-17 04:30:58

UroGen Pharma (NASDAQ:URGN) Price Target Cut to $55.00 by Analysts at HC Wainwright

UroGen Pharma (NASDAQ:URGN – Get Free Report) had its price target decreased by equities researchers at HC Wainwright from $64.00 to $55.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 408.32% from the stock’s previous close. […] - 2025-03-13 04:41:05

UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a report issued on Monday morning,Benzinga reports. D. Boral Capital currently has a $25.00 target price on the stock. Other research analysts have also issued reports about the company. LADENBURG THALM/SH SH started coverage on UroGen Pharma in […] - 2025-03-11 03:50:47

Oppenheimer & Co. Inc. Purchases Shares of 11,875 UroGen Pharma Ltd. (NASDAQ:URGN)

Oppenheimer & Co. Inc. acquired a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,875 shares of the company’s stock, valued at approximately $126,000. Several other […] - 2025-03-10 06:16:51

UroGen Pharma (NASDAQ:URGN) Receives “Buy” Rating from HC Wainwright

UroGen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $64.00 price objective on the stock. URGN has been the topic of several other reports. D. Boral Capital reiterated a […] - 2025-02-27 06:44:57

UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $25.00 target price on the stock. UroGen Pharma Trading Down 1.9 % NASDAQ:URGN opened at $10.56 on Tuesday. The company has a debt-to-equity ratio of […] - 2025-02-19 04:56:52

Back to Listing

Disclaimer